A Phase 3, multicentre, open label, randomized, parallel group Study to Compare Efficacy,Safety and Immunogenicity of Biosimilar Recombinant Insulin Aspart Mix 30 (Manufactured by BioGenomics Limited) with NovoMix 30®(Manufactured by Novo Nordisk), in Diabetes Mellitus patients

开始日期2024-05-04

申办/合作机构

Biogenomics Ltd.

CTRI/2022/09/045313 / Not yet recruiting临床1期

A double-blind, randomized, single-center, two treatment, four period, two sequence, replicate crossover, euglycemic clamp study to demonstrate equivalence in the pharmacokinetic and pharmacodynamic properties of Insulin Glargine 100 IU/mL of BioGenomics Limited and LantusÂ® (Insulin Glargine 100 IU/mL of Sanofi-Aventis) in healthy, adult, human male subjects under fasting condition

开始日期2022-11-01

申办/合作机构

Biogenomics Ltd.

CTRI/2022/06/043169 / Completed临床1期

A Randomized, Double Blind, Single Center, Two Treatment, Two-Period, TwoSequence, Crossover, Euglycemic clamp study to demonstrate equivalence in thePharmacokinetic and Pharmacodynamic properties of Insulin Aspart Mix 30 ofBioGenomics Limited and NovoMix® 30 of Novo Nordisk in healthy, adult, humanmale subjects under fasting condition.

开始日期2022-06-14

申办/合作机构

Biogenomics Ltd.

100 项与 Biogenomics Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Biogenomics Ltd. 相关的专利（医药）

登录后查看更多信息

项与 Biogenomics Ltd. 相关的文献（医药）

2023-09-01·BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart.

Article

作者: Sonar, Sanjay M ; Lona, Jeseena ; Deshmane, Rutuja B ; Thappa, Damodar K ; Mishra, Akshay G ; Ghade, Nikhil S ; Krishnan, Archana R

BACKGROUNDBioassays are used to identify the pharmacological activity of new or chemically unknown compounds, as well as their undesirable effect, including toxicity. Biological assays are also required to ensure the quality, safety, and efficacy of recombinant biologics to confirm its biosimilarity to its originator. In the present study, analytical similarity between the biosimilar and its innovator is established by in vitro bioassays.OBJECTIVEThe objective of this study was to show the comparative in vitro characterization of the recombinant insulin aspart from BioGenomics with its originator insulin aspart, using relevant biological assays.METHODSIn vitro assays such as receptor binding, receptor autophosphorylation, glucose uptake, and mitogenic potential were analyzed for biological characterization of BioGenomics recombinant insulin aspart (BGL-ASP) manufactured by BioGenomics Limited and NovoRapid^® as the reference medicinal product (RMP) manufactured by Novo Nordisk. Insulin receptor binding was studied by a state-of-the-art method, surface plasmon resonance (SPR) for biomolecular interactions. The receptor autophosphorylation assay measures the phosphorylated insulin receptor in cell lysates. The glucose uptake assay measures the uptake of glucose by 3T3-L1 cells in the presence of insulin. Lipogenesis was studied in treated 3T3-L1 cells by detecting the accumulation of lipid droplets in the cells. Mitogenic effect was studied by cell proliferation assay using MCF-7 cells. A rabbit bioidentity test was performed by measuring the sudden decrease in blood glucose in the presence of insulin.RESULTSThe binding studies showed that the affinity of BGL-ASP was highly comparable to NovoRapid^®. Insulin receptor autophosphorylation, glucose uptake, and lipogenesis demonstrated high similarity to the RMP. The mitogenic assay for BGL-ASP did not show any proliferative effect and was comparable to the RMP. The in vivo bioidentity test showed that the BGL-ASP is highly similar to the innovator, NovoRapid^®.CONCLUSIONThe biological characterization studies of BGL-ASP demonstrated high binding and functional similarity to NovoRapid^®.

Scientific Reports

Comparative physicochemical and structural characterisation studies establish high biosimilarity between BGL-ASP and reference insulin aspart

Article

作者: Thappa, Damodar K ; Krishnan, Archana R ; Sonar, Sanjay M ; Ghade, Nikhil S ; Lona, Jeseena

AbstractBiosimilar insulin analogues are increasing market access for diabetic patients globally. Scientific establishment of biosimilarity is cornerstone of this key change in the medical landscape. BGL-ASP is a biosimilar insulin aspart developed by BioGenomics Limited, India. BioGenomics has considered a stepwise approach in generating the totality of evidence required to establish similarity with reference product. Insulin aspart is a recombinant rapid-acting human insulin analogue utilised in the treatment of type-1 and type-2 diabetes mellitus. The single amino acid substitution at position B28 where proline is replaced with aspartic acid results in a decreased propensity to form hexamers, thus increasing the absorption rate on subcutaneous administration compared to native insulin. In order to establish the safety and efficacy of BGL-ASP, the critical quality attributes (CQAs) of BGL-ASP are identified based on the impact created on biological activity, pharmacokinetic/pharmacodynamic (PK/PD), immunogenicity and safety. The CQAs of insulin aspart are related to product structure, purity and functionality and are characterised using a series of state-of-the-art orthogonal analytical tools. The primary protein sequence, the secondary, tertiary and quaternary structure are found to be highly similar for BGL-ASP and reference product. The product related impurities of insulin aspart and the assay content are determined using high performance liquid chromatography (HPLC) based analysis and is similar for BGL-ASP and reference insulin aspart sourced from United States of America (US), Europe Union (EU) and India. The safety, efficacy and immunogenicity of BGL-ASP is also found to be comparable with reference product and is confirmed through the clinical trials conducted as recommended by International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) and European Medicines Agency (EMA) guidelines. The data encompassed in this study demonstrates that reference insulin aspart and BGL-ASP are highly similar in terms of structural, physicochemical, and biological properties, thus confirming its safety and efficacy for usage as potential alternative economical medicinal treatment for diabetes mellitus.

Comparative physicochemical and structural characterisation studies establish high Biosimilarity between BGL-ASP and Reference Insulin Aspart

作者: Thappa, Damodar ; Krishnan, Archana ; Sonar, Sanjay ; Lona, Jeseena ; Ghade, Nikhil

AbstractBiosimilar insulin analogues are increasing market access for diabetic patients globally. Scientific establishment of biosimilarity is cornerstone of this key change in the medical landscape. BGL-ASP is a biosimilar insulin aspart developed by BioGenomics Limited, India. BioGenomics has considered a stepwise approach in generating the totality of evidence required to establish similarity with reference product. Insulin aspart is a recombinant rapid-acting human insulin analogue utilised in the treatment of type-1 and type-2 diabetes mellitus. The single amino acid substitution at position B28 where proline is replaced with aspartic acid results in a decreased propensity to form hexamers, thus increasing the absorption rate on subcutaneous administration compared to native insulin. In order to establish the safety and efficacy of BGL-ASP, the critical quality attributes (CQAs) of BGL-ASP are identified based on the impact created on biological activity, pharmacokinetic/ pharmacodynamic (PK/PD), immunogenicity and safety. The CQAs of insulin aspart are related to product structure, purity and functionality and are characterised using a series of state-of-the-art orthogonal analytical tools. The primary protein sequence, the secondary, tertiary and quaternary structure are found to be highly similar for BGL-ASP and reference product. The product related impurities of insulin aspart and the assay content are determined using high performance liquid chromatography (HPLC) based analysis and is similar for BGL-ASP and reference insulin aspart sourced from United States of America (US), Europe Union (EU) and India. The safety, efficacy and immunogenicity of BGL-ASP is also found to be comparable with reference product and is confirmed through the clinical trials conducted as recommended by International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) and European Medicines Agency (EMA) guidelines. The data encompassed in this study demonstrates that reference insulin aspart and BGL-ASP are highly similar in terms of structural, physicochemical, and biological properties, thus confirming its safety and efficacy for usage as potential alternative economical medicinal treatment for diabetes mellitus.

100 项与 Biogenomics Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Biogenomics Ltd. 相关的转化医学

登录后查看更多信息